|
1
|
Breuer ML, Cuypers HT and Berns A:
Evidence for the involvement of pim-2, a new common proviral
insertion site, in progression of lymphomas. EMBO J. 8:743–748.
1989.PubMed/NCBI
|
|
2
|
Yoshida S, Kaneita Y, Aoki Y, Seto M, Mori
S and Moriyama M: Identification of heterologous translocation
partner genes fused to the BCL6 gene in diffuse large B-cell
lymphomas: 5′-RACE and LA-PCR analyses of biopsy samples. Oncogene.
18:7994–7999. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Amson R, Sigaux F, Przedborski S, Flandrin
G, Givol D and Telerman A: The human protooncogene product p33pim
is expressed during fetal hematopoiesis and in diverse leukemias.
Proc Natl Acad Sci USA. 86:pp. 8857–8861. 1989; View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Asano J, Nakano A, Oda A, Amou H, Hiasa M,
Takeuchi K, Miki H, Nakamura S, Harada T, Fujii S, et al: The
serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in
myeloma cells. Leukemia. 25:1182–1188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dai H, Li R, Wheeler T, Diaz de Vivar A,
Frolov A, Tahir S, Agoulnik I, Thompson T, Rowley D and Ayala G:
Pim-2 upregulation: Biological implications associated with disease
progression and perinueral invasion in prostate cancer. Prostate.
65:276–286. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gong J, Wang J, Ren K, Liu C, Li B and Shi
Y: Serine/threonine kinase Pim-2 promotes liver tumorigenesis
induction through mediating survival and preventing apoptosis of
liver cell. J Surg Res. 153:17–22. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Z, Zhang Y, Gu JJ, Davitt C, Reeves R
and Magnuson NS: Pim-2 phosphorylation of p21(Cip1/WAF1) enhances
its stability and inhibits cell proliferation in HCT116 cells. Int
J Biochem Cell Biol. 42:1030–1038. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van der Lugt NM, Domen J, Verhoeven E,
Linders K, van der Gulden H, Allen J and Berns A: Proviral tagging
in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads
to compensatory activation of Pim-2. EMBO J. 14:2536–2544.
1995.PubMed/NCBI
|
|
9
|
Morishita D, Katayama R, Sekimizu K,
Tsuruo T and Fujita N: Pim kinases promote cell cycle progression
by phosphorylating and down-regulating p27Kip1 at the
transcriptional and posttranscriptional levels. Cancer Res.
68:5076–5085. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Losman J, Chen XP, Jiang H, Pan PY,
Kashiwada M, Giallourakis C, Cowan S, Foltenyi K and Rothman P:
IL-4 signaling is regulated through the recruitment of
phosphatases, kinases, and SOCS proteins to the receptor complex.
Cold Spring Harb Symp Quant Biol. 64:405–416. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cohen AM, Grinblat B, Bessler H, Kristt D,
Kremer A, Schwartz A, Halperin M, Shalom S, Merkel D and Don J:
Increased expression of the hPim-2 gene in human chronic
lymphocytic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma.
45:951–955. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gomez-Abad C, Pisonero H, Blanco-Aparicio
C, Roncador G, González-Menchén A, Martinez-Climent JA, Mata E,
Rodríguez ME, Muñoz-González G, Sánchez-Beato M, et al: PIM2
inhibition as a rational therapeutic approach in B-cell lymphoma.
Blood. 118:5517–5527. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu J, Zavorotinskaya T, Dai Y, Niu XH,
Castillo J, Sim J, Yu J, Wang Y, Langowski JL and Holash J: Pim2 is
required for maintaining multiple myeloma cell growth through
modulating TSC2 phosphorylation. Blood. 122:1610–1620. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Harper JW, Elledge SJ, Keyomarsi K,
Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley
L, Swindell E, et al: Inhibition of cyclin-dependent kinases by
p21. Mol Biol Cell. 6:387–400. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Harbour JW, Luo RX, Dei Santi A, Postigo
AA and Dean DC: Cdk phosphorylation triggers sequential
intramolecular interactions that progressively block Rb functions
as cells move through G1. Cell. 98:859–869. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mlynarczyk C and Fåhraeus R: Endoplasmic
reticulum stress sensitizes cells to DNA damage-induced apoptosis
through p53-dependent suppression of p21(CDKN1A). Nat Commun.
5:50672014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gartel AL and Tyner AL: Transcriptional
regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res. 246:280–289.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gartel AL, Serfas MS and Tyner AL:
p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med.
213:pp. 138–149. 1996; View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weinberg RA: The retinoblastoma protein
and cell cycle control. Cell. 81:323–330. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bertoli C, Skotheim JM and de Bruin RA:
Control of cell cycle transcription during G1 and S phases. Nat Rev
Mol Cell Biol. 14:518–528. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lowe SW and Lin AW: Apoptosis in cancer.
Carcinogenesis. 21:485–495. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Amaravadi R and Thompson CB: The survival
kinases Akt and Pim as potential pharmacological targets. J Clin
Invest. 115:2618–2624. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang JX, Mikami K, Venugopal S, Li Y and
Török NJ: Apoptotic body engulfment by hepatic stellate cells
promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent
pathways. J Hepatol. 51:139–148. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gartel AL and Radhakrishnan SK: Lost in
transcription: p21 repression, mechanisms, and consequences. Cancer
Res. 65:3980–3985. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Loewer A, Batchelor E, Gaglia G and Lahav
G: Basal dynamics of p53 reveal transcriptionally attenuated pulses
in cycling cells. Cell. 142:89–100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hogan C, Hutchison C, Marcar L, Milne D,
Saville M, Goodlad J, Kernohan N and Meek D: Elevated levels of
oncogenic protein kinase Pim-1 induce the p53 pathway in cultured
cells and correlate with increased Mdm2 in mantle cell lymphoma. J
Biol Chem. 283:18012–18023. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ren K, Zhang W, Shi Y and Gong J: Pim-2
activates API-5 to inhibit the apoptosis of hepatocellular
carcinoma cells through NF-kappaB pathway. Pathol Oncol Res.
16:229–237. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hammerman PS, Fox CJ, Cinalli RM, Xu A,
Wagner JD, Lindsten T and Thompson CB: Lymphocyte transformation by
Pim-2 is dependent on nuclear factor-kappaB activation. Cancer Res.
64:8341–8348. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
White E: The pims and outs of survival
signaling: Role for the Pim-2 protein kinase in the suppression of
apoptosis by cytokines. Genes Dev. 17:1813–1816. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xia Y, Shen S and Verma IM: NF-κB, an
active player in human cancers. Cancer Immunol Res. 2:823–830.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fox CJ, Hammerman PS, Cinalli RM, Master
SR, Chodosh LA and Thompson CB: The serine/threonine kinase Pim-2
is a transcriptionally regulated apoptotic inhibitor. Genes Dev.
17:1841–1854. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ghosh S, Tergaonkar V, Rothlin CV, Correa
RG, Bottero V, Bist P, Verma IM and Hunter T: Essential role of
tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and
cell survival. Cancer Cell. 10:215–226. 2006. View Article : Google Scholar : PubMed/NCBI
|
